Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inducing Durable Immunological Control of HIV-1 Through Administration of Long-acting Broadly Neutralizing Antibodies and Low-dose Anti-PD-1 - a Randomized, Double-blinded, Placebocontrolled Trial (the IDUNN Trial)

NCT07820813 is registered in ClinicalTrials.gov with Ole Schmeltz Søgaard as lead sponsor.

NCT NCT07820813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07820813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inducing Durable Immunological Control of HIV-1 Through Administration of Long-acting Broadly Neutralizing Antibodies and Low-dose Anti-PD-1 - a Randomized, Double-blinded, Placebocontrolled Trial (the IDUNN Trial)
Lead sponsor
Ole Schmeltz Søgaard
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
September 15, 2030
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1